- Home
- » Tags
- » Benserazide
Top View
- Jack Deruiter, Principles of Drug Action 2, Fall 2001
- Management of Parkinson's Disease: an Evidence-Based Review
- Levodopa + Benserazide)
- Launch of Ongentys® Tablets 25Mg, a Peripheral COMT Inhibitor in Japan
- Decentralised Procedure Public Assessment Report Tolcapon
- MOTION (Safinamide Add-On to Dopamine Agonist in Early
- DAPH 761 Name______Applied Pharmacology Dr
- Attachment: Product Information for Opicapone
- Treatment of Motor Symptoms in Idiopathic Parkinson's Disease
- Neuroleptic-Induced Parkinson's Syndrome: Clinical
- Assessment of Safety and Efficacy of Safinamide As a Levodopa Adjunct in Patients with Parkinson Disease and Motor Fluctuations a Randomized Clinical Trial
- Systematic Analysis of the Transcriptome Profiles and Co-Expression Networks of Tumour Endothelial Cells Identifies Several Tumo
- Phenotype Microarrays™
- PRODUCT MONOGRAPH Prprolopa®
- 022454Orig1s000
- FDA-Approved Drug Library Mini (96-Well)
- Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
- Parkinson's Disease: Carbidopa, Nausea, and Dyskinesia
- Levodopa for Parkinson's
- Comtan, Film Coated Tablet
- Opposite Sexual Dimorphism of 3,4-Dihydroxyphenylalanine Decarboxylase in the Kidney and Small Intestine of Mice
- Australian Public Assessment Report for Safinamide
- Levodopa/Benserazide Microsphere (LBM) Prevents L-Dopa Induced Dyskinesia by Inactivation of The
- Ongentys, INN-Opicapone
- Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Non-Lipid Benzofuran Ethanolamine Structures
- Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures S
- New Zealand Data Sheet Tasmar®
- Tasmar, INN-Tolcapone
- (12) Patent Application Publication (10) Pub. No.: US 2004/0101523 A1 Reitz Et Al
- Dietary Influence of Tyrosine and Phenylalanine on the Response of B16 Melanoma to Carbidopa-Levodopa Methyl Ester Chemotherapy1
- Novel Drugs Used in the Parkinson's Disease
- TASMAR® (Tolcapone) TABLETS
- A Peripheral COMT Inhibitor for the Improvement of Parkinson’S Disease Patients with Motor Fluctuations
- Randomized, Placebo-Controlled Study of Tolcapone in Patients with Fluctuating Parkinson Disease Treated with Levodopa-Carbidopa
- Ongentys, INN-Opicapone
- Pharmacological Antagonism of Histamine H2R Ameliorated L-Dopaeinduced Dyskinesia Via Normalization of GRK3 and by Suppressing Fosb and ERK in PD
- CDR Clinical Review Report for Onstryv
- Neurological Disease
- Opicapone: from Preclinical Data to Real-World Evidence
- L-Dopa and Dopamine Enhance the Formation of Aggregates Under Proteasome Inhibition in PC12 Cells
- Development of a HPLC/MS/MS Methodology for Determining 3-O-Methyldopa in Human Plasma and Its Application in a Bioequivalence Study
- Key Information for Hospital Pharmacists Introduction
- Supplementary Material
- Cross Discipline Team Leader Review
- Therapeutic Targeting of BRCA1-Mutated Breast Cancers with Agents That Activate DNA Repair
- Benserazide and Levodopa
- Rasagiline-Associated Hypersexuality
- Maximizing PD Medications: How to Get the Most out of Your Treatment Plan
- View Full Page
- Role of Kynurenine Pathway in Oxidative Stress During Neurodegenerative Disorders
- Known Bioactive Library: LOPAC 1
- Consumer Medicine Information Madopar
- SL25.1131, a New, Reversible and Mixed Inhibitor of MAO-A And